Table 4.
Comparison
|
miRNA
|
AUC
|
Sensitivity
|
Specificity
|
Ref.
|
HC | miR-125b + miR-27a + AFP1 | 0.937 | 0.909 | 0.933 | [30] |
HC | miR-125b + miR-223 + miR-27a + miR-26a + AFP | 0.945 | 0.910 | 0.933 | [30] |
HC | miR-125b + miR-223 + miR-27a + miR-26a + AFP2 | 0.972 | 0.944 | 0.900 | [30] |
HC | miR-125b + miR-223 + miR-27a + miR-26a + AFP1 | 0.936 | 0.907 | 0.933 | [30] |
HC | miR-125b + miR-223 + miR-27a + miR-26a + AFP1,2 | 0.956 | 0.800 | 1.000 | [30] |
HBV-carriers | miR-20a-5p + miR-320a + miR-324-3p + miR-375 + AFP | 0.789 | 0.700 | 0.775 | [231] |
HBV-carriers | miR-20a-5p + miR-320a + miR-324-3p + miR-375 + AFP | 0.767 | 0.640 | 0.838 | [231] |
CHB | miR-96 + AFP | 0.889 | 0.836 | 0.824 | [34] |
CHB | miR-126 + AFP | 0.920 | 0.840 | 0.920 | [32] |
CHB | miR-142-3p + AFP | 0.910 | 0.860 | 0.940 | [32] |
CHB | miR-224 + AFP | 0.867 | 0.875 | 0.765 | [11] |
CHB | miR-125b + miR-27a + AFP1 | 0.722 | 0.600 | 0.833 | [30] |
CHB | miR-125b + miR-223 + miR-27a + miR-26a + AFP | 0.790 | 0.689 | 0.867 | [30] |
CHB | miR-125b + miR-223 + miR-27a + miR-26a + AFP2 | 0.833 | 0.820 | 0.767 | [30] |
CHB | miR-125b + miR-223 + miR-27a + miR-26a + AFP1 | 0.728 | 0.582 | 0.867 | [30] |
CHB | miR-125b + miR-223 + miR-27a + miR-26a + AFP1,2 | 0.812 | 0.704 | 0.833 | [30] |
CHB | miR-126 + miR-142-3p + AFP | 0.930 | 0.880 | 0.970 | [32] |
HBV-DN | let-7b + AFP | 0.706 | 0.508 | 0.767 | [233] |
HBV-DN | miR-122 + AFP | 0.714 | 0.792 | 0.533 | [233] |
HBV-LC | miR-99a + AFP | 0.780 | 0.719 | 0.828 | [232] |
HBV-LC | miR-101 + AFP | 0.973 | 0.966 | 0.879 | [24] |
HBV-LC | miR-122 + AFP + PIVKA-II | 0.918 | 0.910 | 0.880 | [37] |
HBV-LC | miR-126 + AFP | 0.897 | 0.800 | 0.790 | [32] |
HBV-LC | miR-142-3p + AFP | 0.899 | 0.850 | 1.000 | [32] |
HBV-LC | miR-205 + AFP | 0.893 | 0.750 | 0.860 | [36] |
HBV-LC | miR-224 + AFP | 0.844 | 0.969 | 0.641 | [11] |
HBV-LC | miR-126 + miR-142-3p + AFP | 0.939 | 0.850 | 0.840 | [32] |
CHB + HBV-LC | miR-224 + AFP | 0.857 | 0.875 | 0.722 | [11] |
Comparing early-stage hepatitis B virus-associated hepatocellular carcinoma patients to patients with other stages.
Adjusting for gender and age differences.
HC: Healthy control; CHB: Chronic hepatitis B patient; HBV: Hepatitis B virus; HBV-DN: Hepatitis B virus-related dysplastic nodule patient; HBV-LC: Hepatitis B virus-related liver cirrhosis patient; AFP: Alpha fetoprotein; PIVKA-II: Prothrombin induced by vitamin K deficiency or antagonist- II; AUC: Area under the receiver operating characteristic curve; miRNAs: MicroRNAs.